Key Takeaways
- • Vermont Senate advanced H.583, legislation that would restrict private equity and hedge funds from making medical decisions in healthcare facilities, though the bill no longer contains an outright prohibition on PE involvement in the state's healthcare system.
- • The bill's original scope was significantly narrowed during House committee review after hospitals and physician groups warned that strict PE restrictions could limit access to capital and prevent outsourcing of administrative functions.
- • The legislation was prompted by the Cerberus Capital Management case involving Steward Health Care, where PE investors realized $800 million in profits while the hospital operator accumulated extreme debt, failed to pay vendors and employees, and triggered medical device withholding that compromised patient care.
- • House sponsor Rep. Alyssa Black (D-Essex Town) expressed concern that the final bill "still leaves Vermont very vulnerable," stating it accomplishes nothing substantive to prevent PE encroachment on clinical healthcare delivery.
- • Similar regulatory efforts are advancing in other states, including Maine's LD 2201 and Connecticut's SB 196, which implement transaction review processes and restrict sale-leaseback arrangements involving PE firms and hedge funds in healthcare.
Summary
Vermont's Senate advanced H.583 on Wednesday, a bill intended to limit private equity and hedge fund involvement in the state's clinical healthcare operations. The legislation would confine PE and hedge fund decision-making authority to business matters only, excluding involvement in medical decisions. However, the bill represents a substantially weakened version of its original intent: it no longer contains a blanket prohibition on PE or hedge fund participation in Vermont's healthcare system.
The Vermont Health Care Advocate's Office drafted the original proposal as a defensive measure following the deterioration of Steward Health Care, a Texas-based hospital operator with more than 30 facilities across the country. Cerberus Capital Management, the controlling PE investor, sold its stake and realized approximately $800 million in profits, while the hospital group's CEO secured over $250 million in compensation. Subsequently, Steward Health Care defaulted on vendor and employee payments, accumulating such severe debt that medical device suppliers withheld equipment—a shortage that directly compromised patient care through understaffing and reduced service quality.
During House committee proceedings this spring, the legislation faced significant opposition from hospital networks and physician organizations, which argued that stringent PE restrictions would curtail access to essential growth capital and prevent healthcare operators from delegating complex administrative functions to more specialized managers. This institutional pushback substantially diluted the bill's regulatory scope.
Rep. Alyssa Black, the House sponsor, characterized the final legislation as inadequate protection. "We have done nothing—nothing—to stop it," Black stated, emphasizing that the compromise bill leaves Vermont vulnerable to PE expansion in clinical settings. Black cited evidence that private equity participation in healthcare systematically decreases quality, increases costs, and has resulted in bankruptcies and patient mortality.
Vermont's legislative effort reflects a broader regional trend. Maine has enacted LD 2201, which mandates a 180-day review and approval process before PE firms or hedge funds can execute healthcare transactions. Connecticut's SB 196 similarly targets PE presence through restrictions on sale-leaseback arrangements in healthcare facilities.
The Vermont Health Care Advocate's Office drafted the original proposal as a defensive measure following the deterioration of Steward Health Care, a Texas-based hospital operator with more than 30 facilities across the country. Cerberus Capital Management, the controlling PE investor, sold its stake and realized approximately $800 million in profits, while the hospital group's CEO secured over $250 million in compensation. Subsequently, Steward Health Care defaulted on vendor and employee payments, accumulating such severe debt that medical device suppliers withheld equipment—a shortage that directly compromised patient care through understaffing and reduced service quality.
During House committee proceedings this spring, the legislation faced significant opposition from hospital networks and physician organizations, which argued that stringent PE restrictions would curtail access to essential growth capital and prevent healthcare operators from delegating complex administrative functions to more specialized managers. This institutional pushback substantially diluted the bill's regulatory scope.
Rep. Alyssa Black, the House sponsor, characterized the final legislation as inadequate protection. "We have done nothing—nothing—to stop it," Black stated, emphasizing that the compromise bill leaves Vermont vulnerable to PE expansion in clinical settings. Black cited evidence that private equity participation in healthcare systematically decreases quality, increases costs, and has resulted in bankruptcies and patient mortality.
Vermont's legislative effort reflects a broader regional trend. Maine has enacted LD 2201, which mandates a 180-day review and approval process before PE firms or hedge funds can execute healthcare transactions. Connecticut's SB 196 similarly targets PE presence through restrictions on sale-leaseback arrangements in healthcare facilities.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.